Alaunos Therapeutics, Inc.
General ticker "TCRT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.1M (TTM average)
Alaunos Therapeutics, Inc. follows the US Stock Market performance with the rate: 17.8%.
Estimated limits based on current volatility of 6.5%: low 3.12$, high 3.56$
Factors to consider:
- Total employees count: 34 as of 2022
- Top business risk factors: Strategic risks and growth management, Operational and conduct risks, Manufacturing risks, Cybersecurity threats, Regulatory and compliance
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.32$, 4.68$]
- 2025-12-31 to 2026-12-31 estimated range: [1.22$, 4.05$]
Financial Metrics affecting the TCRT estimates:
- Positive: with PPE of -0.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -157.85 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 74.88 > 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term TCRT quotes
Long-term TCRT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $3.06MM | $0.01MM | $0.01MM |
| Operating Expenses | $38.16MM | $34.27MM | $4.82MM |
| Operating Income | $-35.10MM | $-34.27MM | $-4.81MM |
| Non-Operating Income | $-2.62MM | $-0.87MM | $0.13MM |
| Interest Expense | $3.15MM | $1.92MM | $0.00MM |
| R&D Expense | $25.02MM | $16.28MM | $0.36MM |
| Income(Loss) | $-37.73MM | $-35.14MM | $-4.68MM |
| Profit(Loss)* | $-37.73MM | $-35.14MM | $-4.68MM |
| Stockholders Equity | $38.55MM | $6.31MM | $2.06MM |
| Inventory | $13.94MM | $0.00MM | $0.00MM |
| Assets | $64.94MM | $8.26MM | $2.75MM |
| Operating Cash Flow | $-29.23MM | $-30.14MM | $-4.97MM |
| Capital expenditure | $0.22MM | $0.20MM | $0.00MM |
| Investing Cash Flow | $-0.19MM | $1.35MM | $0.00MM |
| Financing Cash Flow | $6.37MM | $-18.14MM | $0.00MM |
| Earnings Per Share** | $-26.07 | $-21.97 | $-2.92 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.